PRTC
Puretech Health·NASDAQ
--
--(--)
--
--(--)
3.24 / 10
Netural
PRTC's fundamentals score only 3.2/10, indicating poor health. Key concerns include a high Days sales outstanding of 194.8784 (Group 1) and an Interest coverage ratio of 27.5802 (Group 1), both historically associated with modest returns and limited confidence. While revenue growth is impressive at 542.7083% YoY, it is offset by other weaknesses, leading to a selective view and the need for careful risk assessment.
Analysis Checks(4/4)
Total operating revenue (YoY growth rate %)
Value542.71
Score2/3
Weight68.10%
1M Return1.11%
Value542.71
Score2/3
Weight68.10%
1M Return1.11%
Interest coverage ratio (EBIT / Interest expense) (%)
Value27.58
Score2/3
Weight-63.59%
1M Return-1.11%
Value27.58
Score2/3
Weight-63.59%
1M Return-1.11%
Days sales outstanding
Value194.88
Score2/3
Weight69.26%
1M Return1.10%
Value194.88
Score2/3
Weight69.26%
1M Return1.10%
Operating revenue (YoY growth rate %)
Value542.71
Score2/3
Weight26.24%
1M Return0.43%
Value542.71
Score2/3
Weight26.24%
1M Return0.43%
Total operating revenue (YoY growth rate %)
Value542.71
Score2/3
Weight68.10%
1M Return1.11%
Value542.71
Score2/3
Weight68.10%
1M Return1.11%
Days sales outstanding
Value194.88
Score2/3
Weight69.26%
1M Return1.10%
Value194.88
Score2/3
Weight69.26%
1M Return1.10%
Interest coverage ratio (EBIT / Interest expense) (%)
Value27.58
Score2/3
Weight-63.59%
1M Return-1.11%
Value27.58
Score2/3
Weight-63.59%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value542.71
Score2/3
Weight26.24%
1M Return0.43%
Value542.71
Score2/3
Weight26.24%
1M Return0.43%
Is PRTC undervalued or overvalued?
- PRTC scores 3.24/10 on fundamentals and holds a Fair valuation at present. Backed by its -11.48% ROE, 498.89% net margin, 8.58 P/E ratio, 1.18 P/B ratio, and 156.67% earnings growth, these metrics solidify its Netural investment rating.
